August 2, 2023 – FACIT and T-CAIREM announce partnership to commercialize medical artificial intelligence (AI) innovations. The partners intend to harness both T-CAIREM’s innovative translational research in AI and FACIT’s unique commercialization-venture model to build the next generation of Ontario biotechnology companies. The joint mission will accelerate the benefits of AI research to support patients battling cancer.
May 1, 2023 – Watch FACIT President Dr. David O’Neill’s interview with Amanda Lang, host of Taking Stock on BNN Bloomberg. The episode, titled From Idea to Start up, originally aired on April 28, 2023. This was part of a special series about innovation in Canada and some of the challenges and opportunities. FACIT was featured as a “success
March 31, 2023 – The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.
March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.